NephroGenex reports positive results for QT study of Pyridorin

31 December 2014

US clinical stage firm NephroGenex (Nasdaq: NRX) says it has successfully completed a thorough QT/QTc (TQT) cardiac safety study on Pyridorin (pyridoxamine dihydrochloride), a Phase III drug candidate for diabetic nephropathy.

NephroGenex’ shares, down nearly 60% year-to-date according to RTT News, closed yesterday's trading down 1.9% at $4.65. However, in extended trading, the stock gained 118.3% to $10.15.

This study assesses a drug’s risk of QT prolongation and its proarrhythmic potential, and is a standard component of all clinical development programs for new molecular entities. Pyridorin showed no effect on the QT/QTc interval at the expected therapeutic dose of 300mg and at a higher dose of 1,200mg. In previous Phase I and Phase II studies, Pyridorin has shown no effect on the QT/QTc interval in patients with diabetic nephropathy.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK